The impact of major depressive disorder on the short‐ and long‐term outcome of Crohn's disease treatment with infliximab

Abstract

Major depressive disorder is a risk factor for failure to achieve remission with infliximab and for earlier retreatment in patients with active luminal Crohn's disease. Assessment and management of major depressive disorder should be part of the clinical approach to patients with Crohn's disease.